Pradžia › Vilkligės nefritas › Pennsylvania
Vilkligės nefritas klinikiniai tyrimai Pennsylvania
7 tyrimai dėl Vilkligės nefritas ieško dalyvių vietose Pennsylvania.
Miestai Pennsylvania
Oficialus tyrimo tekstas (anglų kalba)
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
- Temple University, Philadelphia
Renkami dalyviai2 fazė
Amžius nuo 18 iki 100 · Visoms lytims · Atnaujinta 2026-10-01 · NCT05268289CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
- Children's Hospital of Philadelphia, Philadelphia
Renkami dalyviai1/2 fazė
Amžius nuo 10 iki 29 · Visoms lytims · Atnaujinta 2026-09-24 · NCT06839976A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
- Fox Chase Cancer Center- Temple BMT, Philadelphia
Renkami dalyviai2 fazė
Amžius nuo 16 iki 70 · Visoms lytims · Atnaujinta 2026-09-17 · NCT07328581VIBRANT: VIB4920 for Active Lupus Nephritis
- Penn State Health Milton S. Hershey Medical Center: Division of Rheumatology, Hershey
- Temple University, Lewis Katz School of Medicine, Department of Medicine: Nephrology, Philadelphia
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-16 · NCT05201469RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Children's Hospital of Philadelphia, Philadelphia
Renkami dalyviai1/2 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-08-26 · NCT06121297PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
- Rheumatic Disease Associates, Ltd., Willow Grove
Renkami dalyviai4 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-08-03 · NCT07611214A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Jefferson Einstein Hospital Philadelphia, Philadelphia
Renkami dalyviai1 fazė
Amžius nuo 12 iki 70 · Visoms lytims · Atnaujinta 2026-05-22 · NCT06308978Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.